CompoAtlas

Noomind

Food supplement declared in France, declaration No 2019-3-287

Noomind (Noomind) is a food supplement declared in France. Status: retiré du marché le 30 October 2023. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
Noomind
Food business operator placing the product on the market
NOOMIND
Status
Retiré du marché le 30 October 2023
Form
Gélule
Daily dose
2 gélules
Directions for use
Prendre deux gélules par jour avec un verre d’eau.
Intended populations
Homme, Femme
Not recommended for (according to the manufacturer)
Femmes allaitantes, Enfants (moins de 12 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous antidiabétiques
Objectives stated by the manufacturer (these are not authorised claims)
Mémoire, Sport, Humeur, Concentration

Declaration 294075, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Bacopa monnieri (L.) Wettst.Plante entièrePoudre (de plantes séchées ou broyées)300 mg
Panax ginseng C.A.Mey.RacineAutre extrait sec150 mg

Other active ingredients

NamePer day
Tyrosinenot declared
Théaninenot declared
Caféinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
MéthylcobalamineVitamine B12pas d'effet indésirable définidose annulée par le Conseil d'État en 2011
Chlorhydrate de pyridoxineVitamine B612 mg2 mg

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Consommer dans le cadre d’un régime alimentaire équilibré. Ne pas dépasser les doses journalières recommandées. Contient de la caféine (200 mg / 2 gélules). Déconseillé chez les femmes enceintes et allaitantes, ainsi que chez les personnes sous traitement antidiabétique.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Brand : Noomind

Enter to analyse, Shift+Enter for a new line